
Olwen Hahn, MD, discusses the impact of trastuzumab emtansine on the treatment of patients with HER2-positive breast cancer.

Your AI-Trained Oncology Knowledge Connection!


Olwen Hahn, MD, discusses the impact of trastuzumab emtansine on the treatment of patients with HER2-positive breast cancer.

Olwen Hahn, MD, discusses the convenience of the fixed-dose combination of trastuzumab and pertuzumab in a subcutaneous formulation in HER2-positive breast cancer.

Olwen Hahn, MD, discusses future research directions with tucatinib (Tukysa) in the treatment of patients with breast cancer.

Published: April 23rd 2021 | Updated:

Published: May 3rd 2021 | Updated: